UNSPSC 51172178: Pargeverine hydrochloride

This classification denotes an antispasmotic agent with the molecular formula C21H23NO3.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XT63P694CJ. European Medicines Agency schedules pargeverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22269. The term pargeverine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule pargeverine hydrochloride under HS 29221980 and SITC 51461.

As of Q4 2014, PARGEVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pargeverine hydrochloride bears US NLM NCI C97987. SMILES: CN(C)CCOC(=O)C(C1CCCCC1)(C2CCCCC2)OCC#C.CL.

UNSPSC 51172178 Pargeverine hydrochloride is a Commodity code that encompasses pharmaceutical ingredient supply and related drug-testing chemical products for state and local government agencies. Recent state and local opportunities show the code serving criminal justice and health and human services procurement, though the actual work solicited spans a broader range than the code's narrow product name suggests. Issuing bodies include state health and human services agencies, county criminal justice departments, and multistate cooperative purchasing alliances. The Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated value $600,000 over two years with three optional one-year renewals) illustrates the scope: the county is procuring staffing, lab certification compliance (SAMHSA, TX DPS, or CAP), immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies including oral fluid and hair testing for approximately 25,031 annual tests across two collection sites in Plano and McKinney. Pricing is evaluated on a per-test basis across three service models (screening only, confirmation after screening, screening with automatic confirmation), with best-value award criteria weighting vendor understanding, firm qualifications, client references, and cost equally at 30 points each, plus up to 30 optional points for Phase 2 demonstrations.

Recent activity concentrates in Texas and Minnesota. Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription fulfillment capabilities for self-insured state employee group health plans and Medicaid-related programs, seeking vendor experience with negotiated net pricing models and value-based outcomes agreements outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating jurisdictions through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson); pricing is weighted at 75 percent of evaluation, with contract commencement July 1, 2026. The code shows activity in criminal justice drug-testing operations and state pharmacy benefit program modernization but limited breadth of recent solicitations.